Diabetes mellitus is caused by the defect of the insulin mechanism and characterised by hyperglycemia. Diabetes mellitus is a common disease in humans and is seen in dogs and cats. The disease pathophysiology is the same as that of humans. For this reason, diabetes mellitus in dogs and cats is classified according to medical literature. There is not a certain treatment method for diabetes mellitus. Management of the disease is based on keeping blood glucose within normal limits. Different methods are applied to keep the glycemic index between reference parameters. In recent years, it has been reported that stem cell applications have the ability to regenerate pancreatic beta cells and that stem cell applications can be used in diabetes mellitus cases. Adipose tissue-derived mesenchymal stem cells are used in veterinary medicine as safe and non-complicated applications. When studies on humans and stem cells accessible in veterinary medicine are evaluated, adipose tissue-derived mesenchymal stem cells come to the fore in cases of diabetes. In this case report, we avaluated the results of stem cell application along with insulin and diet in controlling the glycemic index in a cat diagnosed with diabetes. In this case, no side effects were observed, and similar results were obtained with studies conducted on insulin and diet. As a result of this case, the existence of a larger number of patients was emphasized, and the potential reported features of stem cell applications in diabetes cases were emphasized.
30 October 2025 in Turkish Journal of Veterinary Research
Osteochondrodysplasia is a degenerative joint condition caused by a TRPV4 gene mutation, predominantly affecting Scottish Fold cats. This study evaluated the effects of adipose-derived mesenchymal stem cells (MSCs) in two Scottish Fold cats diagnosed with osteochondrodysplasia. Case 1 involved a 3-year-old cat with a one-month history of lameness and joint degeneration, while Case 2 featured a 4-year-old cat with a five-month history of similar symptoms. MSCs were isolated, characterized at passage 3, and administered intra-articularly at a dose of 1 × 10^6 cells/kg body weight. Both cats demonstrated significant clinical improvement, including resolution of lameness and increased mobility, despite persistent radiographic abnormalities. These findings suggest that MSC therapy may effectively alleviate clinical symptoms of osteochondrodysplasia. Further research is needed to explore its long-term efficacy and correlation with imaging outcomes.